Preview of HORIZON (Lp(a)) and ZEUS (IL-6): improved bloodwork is not enough
Louis announces an upcoming discussion of two failed cardiology trials and shares a post arguing treatments should be judged on outcomes, not just lab numbers. In ZEUS, IL-6 and hsCRP fell but the combined risk of heart attack, stroke or CV death was not significantly reduced.
